Shopping Cart
- Remove All
- Your shopping cart is currently empty
SIRT6-IN-3 (compound 8a), a selective SIRT6 inhibitor (IC50 = 7.49 μM), impedes the proliferation of pancreatic ductal adenocarcinoma (PDAC) cells and prompts apoptosis. It enhances the responsiveness of cancer cells to gemcitabine by obstructing the DNA damage repair pathway, thus serving as a valuable tool in pancreatic cancer research [1].
Pack Size | Price | Availability | Quantity |
---|---|---|---|
5 mg | Inquiry | 8-10 weeks | |
50 mg | Inquiry | 8-10 weeks |
Description | SIRT6-IN-3 (compound 8a), a selective SIRT6 inhibitor (IC50 = 7.49 μM), impedes the proliferation of pancreatic ductal adenocarcinoma (PDAC) cells and prompts apoptosis. It enhances the responsiveness of cancer cells to gemcitabine by obstructing the DNA damage repair pathway, thus serving as a valuable tool in pancreatic cancer research [1]. |
Targets&IC50 | HDAC8:102 μM, SIRT1:80.52 μM, HDAC6:96.77 μM, SIRT6:7.46 μM, HDAC3:111.9 μM, SIRT2:92.21 μM |
In vitro | SIRT6-IN-3 at a concentration of 25 μM induces a cell cycle arrest and apoptosis in PDAC cells after 48 hours of treatment [1]. When applied for 72 hours, SIRT6-IN-3 continues to hinder the proliferation of pancreatic cancer cells by inhibiting cellular signaling pathways [1]. |
In vivo | SIRT6-IN-3 exhibits antitumor effects in a murine tumor model [1]. When used in combination with gemcitabine (at a ratio of 2:1), SIRT6-IN-3 enhances the anticancer activity of gemcitabine [1]. |
Molecular Weight | 673.73 |
Formula | C21H30Br3ClN6S |
Cas No. | 3023471-40-8 |
Storage | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.